Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 16/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439131 | 1.00 | HCRTR2 (0.35) | HCRTR2SCN9AROCK2ROCK1ALOX5 | |
| SCHEMBL11423412 | 0.82 | SERPINE1 (0.37) | — | |
| SCHEMBL221501 | 0.82 | — | — | |
| SCHEMBL9275379 | 0.82 | SERPINE1 (0.37) | — | |
| SCHEMBL11422188 | 0.82 | SERPINE1 (0.37) | — | |
| SCHEMBL9747693 | 0.81 | TSHR (0.37) | HCRTR2 | |
| SCHEMBL10710365 | 0.81 | HCRTR2 (0.33) | HCRTR2SCN9AROCK2ROCK1ALOX5 | |
| SCHEMBL18082716 | 0.79 | ATM (0.41) | HCRTR2SCN9AROCK2ROCK1ALOX5 | |
| SCHEMBL12424962 | 0.76 | EPHX1 (0.38) | HCRTR2SCN9AROCK2ROCK1 | |
| SCHEMBL20909081 | 0.76 | NAAA (0.40) | HCRTR2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534913-B2 | Crystalline form of nateglinide | TEVA PHARMACEUTICA INDUSTRIES LTD. (IL) | 2009-05-19 | — | — | US | disclosed |
| US-20080319075-A1 | Polymorphic forms of nateglinide | YAHALOMI RONIT | 2008-12-25 | — | — | US | disclosed |
| US-7420084-B2 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-09-02 | — | — | US | disclosed |
| US-7358390-B2 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-04-15 | — | — | US | disclosed |
| US-20070004804-A1 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICALS USA, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7148376-B2 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-12-12 | — | — | US | disclosed |
| US-20050090552-A1 | Crystalline form with xray powder diffraction pattern peaks at 4.7, 7.4, 13.8 and 17.0+-0.2 but not at 3.8+-0.2 theta; thermal stability | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-04-28 | — | — | US | disclosed |
| US-20050075400-A1 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-04-07 | — | — | US | disclosed |
| EP-1511717-A1 | CRYSTALLINE FORM OF NATEGLINIDE | Teva Pharmaceutical Industries Limited (IL) | 2005-03-09 | — | — | EP | disclosed |
| US-20050014949-A1 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-01-20 | — | — | US | disclosed |
| US-20050014836-A1 | Crystalline form of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-01-20 | — | — | US | disclosed |
| WO-2004067496-A9 | CRYSTALLINE FORM OF NATEGLINIDE | TEVA PHARMA (IL) | 2004-12-09 | — | — | WO | disclosed |
| EP-1467964-A1 | POLYMORPHIC FORMS OF NATEGLINIDE | Teva Pharmaceutical Industries Limited (IL) | 2004-10-20 | — | — | EP | disclosed |
| US-20040181089-A1 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-16 | — | — | US | disclosed |
| WO-2004067496-A1 | CRYSTALLINE FORM OF NATEGLINIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-12 | — | — | WO | disclosed |
| US-20040116526-A1 | Polymorphic forms of nateglinide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-17 | — | — | US | disclosed |
| WO-2004009532-A1 | POLYMORPHIC FORMS OF NATEGLINIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014949-A1 | Polymorphic forms of nateglinide | CCT4, CSNK1D, TTR | HCRTR2 2083/4885SCN9A 192/4885ROCK2 3470/4885 |
| US-20050075400-A1 | Polymorphic forms of nateglinide | CCT4, CSNK1D, TTR | HCRTR2 2083/4885SCN9A 192/4885ROCK2 3470/4885 |
| US-20050014836-A1 | Crystalline form of nateglinide | CCT4, LBR, TTR | HCRTR2 2077/4885SCN9A 319/4885ROCK2 2173/4885 |
| US-20070004804-A1 | Polymorphic forms of nateglinide | CSNK1D, CCT4, LBR | HCRTR2 1840/4885SCN9A 136/4885ROCK2 3235/4885 |
| US-20040181089-A1 | Polymorphic forms of nateglinide | LPXN, CCNY, HDGF | HCRTR2 3148/4885SCN9A 997/4885ROCK2 4232/4885 |
| US-20050090552-A1 | Crystalline form with xray powder diffraction pattern peaks at 4.7, 7.4, 13.8 and 17.0+-0.2 but not at 3.8+-0.2 theta; thermal stability | CCT8, CCT4, LBR | HCRTR2 1826/4885SCN9A 370/4885ROCK2 1256/4885 |
| US-20080319075-A1 | Polymorphic forms of nateglinide | CCT4, CSNK1D, TTR | HCRTR2 2083/4885SCN9A 192/4885ROCK2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.